Cargando…

Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone

Treatment of cancer metastasized to bone is still a challenge due to hydrophobicity, instability, and lack of target specificity of anticancer drugs. Poly (ethylene glycol)-poly (ε-caprolactone) polymer (PEG-PCL) is an effective, biodegradable, and biocompatible hydrophobic drug carrier, but lacks b...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jinsong, Zeng, Youyun, Shi, Shuai, Xu, Lihua, Zhang, Hualin, Pathak, Janak L, Pan, Yihuai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428813/
https://www.ncbi.nlm.nih.gov/pubmed/28507436
http://dx.doi.org/10.2147/IJN.S133787
_version_ 1783235907879436288
author Liu, Jinsong
Zeng, Youyun
Shi, Shuai
Xu, Lihua
Zhang, Hualin
Pathak, Janak L
Pan, Yihuai
author_facet Liu, Jinsong
Zeng, Youyun
Shi, Shuai
Xu, Lihua
Zhang, Hualin
Pathak, Janak L
Pan, Yihuai
author_sort Liu, Jinsong
collection PubMed
description Treatment of cancer metastasized to bone is still a challenge due to hydrophobicity, instability, and lack of target specificity of anticancer drugs. Poly (ethylene glycol)-poly (ε-caprolactone) polymer (PEG-PCL) is an effective, biodegradable, and biocompatible hydrophobic drug carrier, but lacks bone specificity. Polyaspartic acid with eight peptide sequences, that is, (Asp)(8), has a strong affinity to bone surface. The aim of this study was to synthesize (Asp)(8)-PEG-PCL nanoparticles as a bone-specific carrier of hydrophobic drugs to treat cancer metastasized to bone. (1)H nuclear magnetic resonance, Fourier transform infrared spectroscopy, and transmission electron microscopy data showed that (Asp)(8)-PEG-PCL nanoparticles (size 100 nm) were synthesized successfully. (Asp)(8)-PEG-PCL nanoparticles did not promote erythrocyte aggregation. Fluorescence microscopy showed clear uptake of Nile red-loaded (Asp)(8)-PEG-PCL nanoparticles by cancer cells. (Asp)(8)-PEG-PCL nanoparticles did not show cytotoxic effect on MG63 and human umbilical vein endothelial cells at the concentration of 10–800 μg/mL. (Asp)(8)-PEG-PCL nanoparticles bound with hydroxyapatite 2-fold more than PEG-PCL. Intravenously injected (Asp)(8)-PEG-PCL nanoparticles accumulated 2.7-fold more on mice tibial bone, in comparison to PEG-PCL. Curcumin is a hydrophobic anticancer drug with bone anabolic properties. Curcumin was loaded in the (Asp)(8)-PEG-PCL. (Asp)(8)-PEG-PCL showed 11.07% loading capacity and 95.91% encapsulation efficiency of curcumin. The curcumin-loaded (Asp)(8)-PEG-PCL nanoparticles gave sustained release of curcumin in high dose for >8 days. The curcumin-loaded (Asp)(8)-PEG-PCL nanoparticles showed strong antitumorigenic effect on MG63, MCF7, and HeLa cancer cells. In conclusion, (Asp)(8)-PEG-PCL nanoparticles were biocompatible, permeable in cells, a potent carrier, and an efficient releaser of hydrophobic anticancer drug and were bone specific. The curcumin-loaded (Asp)(8)-PEG-PCL nanoparticles showed strong antitumorigenic ability in vitro. Therefore, (Asp)(8)-PEG-PCL nanoparticles could be a potent carrier of hydrophobic anticancer drugs to treat the cancer metastasized to bone.
format Online
Article
Text
id pubmed-5428813
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54288132017-05-15 Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone Liu, Jinsong Zeng, Youyun Shi, Shuai Xu, Lihua Zhang, Hualin Pathak, Janak L Pan, Yihuai Int J Nanomedicine Original Research Treatment of cancer metastasized to bone is still a challenge due to hydrophobicity, instability, and lack of target specificity of anticancer drugs. Poly (ethylene glycol)-poly (ε-caprolactone) polymer (PEG-PCL) is an effective, biodegradable, and biocompatible hydrophobic drug carrier, but lacks bone specificity. Polyaspartic acid with eight peptide sequences, that is, (Asp)(8), has a strong affinity to bone surface. The aim of this study was to synthesize (Asp)(8)-PEG-PCL nanoparticles as a bone-specific carrier of hydrophobic drugs to treat cancer metastasized to bone. (1)H nuclear magnetic resonance, Fourier transform infrared spectroscopy, and transmission electron microscopy data showed that (Asp)(8)-PEG-PCL nanoparticles (size 100 nm) were synthesized successfully. (Asp)(8)-PEG-PCL nanoparticles did not promote erythrocyte aggregation. Fluorescence microscopy showed clear uptake of Nile red-loaded (Asp)(8)-PEG-PCL nanoparticles by cancer cells. (Asp)(8)-PEG-PCL nanoparticles did not show cytotoxic effect on MG63 and human umbilical vein endothelial cells at the concentration of 10–800 μg/mL. (Asp)(8)-PEG-PCL nanoparticles bound with hydroxyapatite 2-fold more than PEG-PCL. Intravenously injected (Asp)(8)-PEG-PCL nanoparticles accumulated 2.7-fold more on mice tibial bone, in comparison to PEG-PCL. Curcumin is a hydrophobic anticancer drug with bone anabolic properties. Curcumin was loaded in the (Asp)(8)-PEG-PCL. (Asp)(8)-PEG-PCL showed 11.07% loading capacity and 95.91% encapsulation efficiency of curcumin. The curcumin-loaded (Asp)(8)-PEG-PCL nanoparticles gave sustained release of curcumin in high dose for >8 days. The curcumin-loaded (Asp)(8)-PEG-PCL nanoparticles showed strong antitumorigenic effect on MG63, MCF7, and HeLa cancer cells. In conclusion, (Asp)(8)-PEG-PCL nanoparticles were biocompatible, permeable in cells, a potent carrier, and an efficient releaser of hydrophobic anticancer drug and were bone specific. The curcumin-loaded (Asp)(8)-PEG-PCL nanoparticles showed strong antitumorigenic ability in vitro. Therefore, (Asp)(8)-PEG-PCL nanoparticles could be a potent carrier of hydrophobic anticancer drugs to treat the cancer metastasized to bone. Dove Medical Press 2017-05-08 /pmc/articles/PMC5428813/ /pubmed/28507436 http://dx.doi.org/10.2147/IJN.S133787 Text en © 2017 Liu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Liu, Jinsong
Zeng, Youyun
Shi, Shuai
Xu, Lihua
Zhang, Hualin
Pathak, Janak L
Pan, Yihuai
Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone
title Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone
title_full Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone
title_fullStr Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone
title_full_unstemmed Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone
title_short Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone
title_sort design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428813/
https://www.ncbi.nlm.nih.gov/pubmed/28507436
http://dx.doi.org/10.2147/IJN.S133787
work_keys_str_mv AT liujinsong designofpolyasparticacidpeptidepolyethyleneglycolpolyecaprolactonenanoparticlesasacarrierofhydrophobicdrugstargetingcancermetastasizedtobone
AT zengyouyun designofpolyasparticacidpeptidepolyethyleneglycolpolyecaprolactonenanoparticlesasacarrierofhydrophobicdrugstargetingcancermetastasizedtobone
AT shishuai designofpolyasparticacidpeptidepolyethyleneglycolpolyecaprolactonenanoparticlesasacarrierofhydrophobicdrugstargetingcancermetastasizedtobone
AT xulihua designofpolyasparticacidpeptidepolyethyleneglycolpolyecaprolactonenanoparticlesasacarrierofhydrophobicdrugstargetingcancermetastasizedtobone
AT zhanghualin designofpolyasparticacidpeptidepolyethyleneglycolpolyecaprolactonenanoparticlesasacarrierofhydrophobicdrugstargetingcancermetastasizedtobone
AT pathakjanakl designofpolyasparticacidpeptidepolyethyleneglycolpolyecaprolactonenanoparticlesasacarrierofhydrophobicdrugstargetingcancermetastasizedtobone
AT panyihuai designofpolyasparticacidpeptidepolyethyleneglycolpolyecaprolactonenanoparticlesasacarrierofhydrophobicdrugstargetingcancermetastasizedtobone